Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115965 | 1.00 | PIN1 (0.45) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL17240945 | 0.96 | PIN1 (0.43) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL2115968 | 0.92 | PIN1 (0.45) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL2115836 | 0.89 | PIN1 (0.47) | PIN1LMNAHSD17B10TSHRALDH1A1 | |
| SCHEMBL2115841 | 0.89 | PIN1 (0.47) | PIN1LMNAHSD17B10TSHRALDH1A1 | |
| SCHEMBL17240946 | 0.88 | MEN1 (0.47) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL28918834 | 0.84 | PIN1 (0.43) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL1964039 | 0.82 | HCAR2 (0.51) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL1964036 | 0.82 | HCAR2 (0.51) | PIN1LMNANPC1HSD17B10TSHR | |
| SCHEMBL2115838 | 0.81 | MEN1 (0.53) | PIN1LMNAHSD17B10ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10994003-B2 | Dimethyl fumarate and vaccination regimens | BIOGEN MA INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3804711-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10959972-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170000873-A1 | Dimethyl Fumarate and Vaccination Regimens | BIOGEN MA INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2016153957-A2 | METHODS AND COMPOSITIONS FOR THE INTRAVENOUS ADMINISTRATION OF FUMARATES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | BIOGEN MA INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-20160115540-A1 | PRODRUGS AND DRUGS | BIOGEN MA INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2999482-A2 | PRODRUGS AND DRUGS | Biogen MA Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | BIOGEN MA INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2014190056-A2 | PRODRUGS AND DRUGS | BIOGEN IDEC MA INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | BIOGEN MA INC. | 2013-11-07 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000873-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | PIN1 2070/4885LMNA 4083/4885NPC1 2876/4885 |
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
| US-20160115540-A1 | PRODRUGS AND DRUGS | CYP2D6, PAICS, UGT2B7 | PIN1 283/4885LMNA 2719/4885NPC1 716/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | PIN1 405/4885LMNA 4576/4885NPC1 4131/4885 |
| US-20260007627-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FH, SLC6A6, SLC6A13 | PIN1 962/4885LMNA 1608/4885NPC1 290/4885 |
| US-20150209318-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE | FH, FAH, MGMT | PIN1 1693/4885LMNA 3411/4885NPC1 1456/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
| US-10959972-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
| US-10994003-B2 | Dimethyl fumarate and vaccination regimens | FH, HLA-DRB1, SDHB | PIN1 2070/4885LMNA 4083/4885NPC1 2876/4885 |
| US-20220072117-A1 | Dimethyl Fumarate and Vaccination Regimens | FH, HLA-DRB1, SDHB | PIN1 2070/4885LMNA 4083/4885NPC1 2876/4885 |
| US-20130295169-A1 | Pharmaceutical Compositions Containing Dimethyl Fumarate | FH, FAH, MGMT | PIN1 1693/4885LMNA 3411/4885NPC1 1456/4885 |
| US-20170354630-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | PIN1 1935/4885LMNA 3109/4885NPC1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.